Loading
RN
RNV Stock: price and insider trades · Australia
RNV: what insiders have been doing
RNV has a thin disclosure history in our data (latest filing: 29 April 2026). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by ASX. They describe what insiders did and are not a recommendation.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 19,913 of 24,148 companies
28.9
score / 100
Value8
Quality50
FCF yld-24%
Earn yld-30%
EV/EBITDA·
ROE-75%
Gross mgn90%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended June 2025 · cache
A$0.07
Analyst consensus
Income statement
RevenueA$271.7k
Gross profitA$244.7k90% margin
EBITDA-A$3.4M-1265% margin
Net income-A$3.7M-1374.2% margin
Valuation
P/Book2.3x
Balance sheet & cash
Market capA$12.6M
Total debtA$21.8k
Free Cash Flow-A$3M
Debt / Equity3%
Profitability & ownership
ROE-74.9%
ROA-47.6%
% insiders58.5%
% institutions1.3%
Last declaration on 29 April 2026
About RNV
RNV is a company operating in the healthcare and pharmaceutical sector, listed on the XASX market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
